RESEARCH OF THE RANGE OF ANTIHYPERTENSIVE MEDICINES AND ANALYSIS OF ITS ECONOMIC AVAILABILITY UNDER THE CONDITIONS OF THE IMPLEMENTATION OF THE GOVERNMENT PROGRAM "AFFORDABLE MEDICINES"

Authors

DOI:

https://doi.org/10.11603/2312-0967.2022.3.13540

Keywords:

arterial hypertension, antihypertensive drugs, assortment research, "Affordable Medicines" program, reimbursement of the cost of medicines

Abstract

The aim of the work. To conduct a study of the antihypertensive drugs' range presented on the pharmaceutical market of Ukraine and the analysis of its socio-economic availability under the conditions of implementation of the government program "Affordable Medicines in Ukraine".

Materials and Methods. The work was performed using official sources of information, data from which were processed, systematized using statistical, logical and graphical methods.

Results and discussion. The analysis of the assortment of antihypertensive drugs as for 2022 showed that 965 trade names of medicinal products were registered in Ukraine, of which 413 products are combined drugs. Among monomedicines, the largest share in the assortment is angiotensin-converting enzyme (ACE) inhibitors - 23.73 %, angiotensin II receptor blockers - 21.79 %, and β-adrenoblockers (β-AB) - 18.32 %. The share of domestically produced medicinal products is 32.8%. As for combined drugs, the largest number of drugs is the following combinations: angiotensin II receptor blockers with diuretics (26.63%), and ACE inhibitors with diuretics (19.85%). The share of domestic manufacturers of combined antihypertensive drugs is only 17.29%.

It was defined that about 31% of antihypertensive drugs from the analyzed assortment are included in the program "Affordable Medicines". There are no combined antihypertensive drugs in the register of drugs subject to reimbursement. Medicinal products of domestic production, which are included in the program of reimbursement of the cost of pharmaceuticals, make up 61.40% of the total number of trade names. Manufacturers present foreign medicines from Hungary, Germany, India, Slovakia, etc. Calculations of DDD surcharge for drugs that are partially reimbursable, accounting for dosage and packaging were carried out.

The largest share of the assortment of all antihypertensive drugs included in the reimbursement program is β-AB (36.84%) and calcium channel blockers (23.39%). Diuretics accounted for only 15.20%. Only one representative from the group of angiotensin II receptor blockers – losartan and ACE inhibitor – enalapril were included in the reimbursement program.

Conclusions. It is necessary to expand the list of medicines from angiotensin II receptor blockers, ACE inhibitors, and combined drugs in the program "Affordable Medicines" to increase the availability of medicines, improve the supply of patients with the necessary medications and implement modern treatment regimens.

Author Biographies

N. V. Malanchuk, I. Horbachevsky Ternopil National Medical University

assistant of the Department of Pharmacy Management, Economics and Technology

M. B. Demchuk, I. Horbachevsky Ternopil National Medical University

PhD (Pharmacy), Associate Professor of the Department of Pharmacy Management, Economics and Technology

T. A. Hroshovyi, I. Horbachevsky Ternopil National Medical University

DSc (Pharmacy), Professor, Head of the Department of Pharmacy Management, Economics and Technology

References

International Society of Hypertension, Hypertension Clinical Practice Guidelines (ISH 2020), Medscape, May 2020. Available from: https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.15026

Guz VS, Zaliska OM. [Analysis of the dynamics of the assortment of medicines in the "Affordable Medicines" program for the treatment of cardiovascular diseases]. Farmatsevtychnyi zhurnal. 2019;3: 21-30. Ukrainian.

Sholoiko N.V., Honchar A.O. [Comparative analysis of the assortment list of drugs for the treatment of arterial hypertension according to domestic and international clinical guidelines]. Farmatsevtychnyi zhurnal. 2022; 77(1)6: 31-39. Ukrainian. DOI: https://doi.org/10.32352/0367-3057.1.22.03

STEPS: prevalence of noncommunicable disease risk factors in Ukraine 2019. Copenhagen: WHO Regional Office for Europe; 2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/336642/WHO-EURO-2020-1468-41218-56060-eng.pdf?Sequence=1&isallowed=y

Baigush YuV, Slobodianiuk MM. [Research on the range and availability of beta-adrenoceptor blockers in the retail segment of the domestic pharmaceutical market]. Sotsialna farmatsiia v okhoroni zdorovia.2016.;2(1):13-21. Ukrainian. DOI: https://doi.org/10.24959/sphhcj.16.29

Tolochko VM, Mishchenko OYa, Adonkina VYu. [Beta-adrenergic blockers: a study of the assortment, socioeconomic availability and consumption volumes in Ukraine]. Scientific Journal "Sciencerise". 2015;12/4(17): 20-26.

State Register of Medicinal Products of Ukraine. Available from: http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlist?Opendocument

ATS/DDD Index of the WHO Center for the Methodology of Statistical Research on Medicines. Available from: https://www.whocc.no/atc_ddd_index/

Poluychak NYu, Demchuk MB, Yuryeva OO, Groshovyi TA. [Study of the range of antihypertensive drugs presented on the pharmaceutical markets of Ukraine and Poland]. Farmatsevtychnyi chasopys. 2015;3: 34-39. Ukrainian.

Demchuk MB., Malanchuk NV., Groshovyi TA. [Retrospective study of the assortment of combined antihypertensive drugs in Ukraine for 2022 compared to 2015]. Farmatsevtychnyi chasopys. 2022;77(5): 12-22. DOI: https://doi.org/10.32352/0367-3057.5.22.02

Assessment of the availability of basic medicines for outpatient treatment in Ukraine. Copenhagen: WHO Regional Office for Europe; 2021. Available from: https://apps.who.int/iris/bitstream/handle/10665/343084/WHO-EURO-2021-2770-42528-59326-ukr.pdf

Order No. 1931, 27.10.2022, Ministry of Health of Ukraine. On the approval of the Register of medicinal products that are subject to reimbursement under the program of state guarantees of medical care for the population. URL: https://zakon.rada.gov.ua/rada/show/v1931282-22#Text

Published

2022-12-30

How to Cite

Malanchuk, N. V., Demchuk, M. B., & Hroshovyi, T. A. (2022). RESEARCH OF THE RANGE OF ANTIHYPERTENSIVE MEDICINES AND ANALYSIS OF ITS ECONOMIC AVAILABILITY UNDER THE CONDITIONS OF THE IMPLEMENTATION OF THE GOVERNMENT PROGRAM "AFFORDABLE MEDICINES". Pharmaceutical Review Farmacevtičnij časopis, (4), 26–34. https://doi.org/10.11603/2312-0967.2022.3.13540

Issue

Section

Pharmaceutical management, marketing and logistics